TAMPA, Fla. — February 5, 2026 — Leads & Copy —
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company, announced its participation in the Corporate Connect Webinar Series hosted by Webull Financial. The virtual event is scheduled for February 10-11, 2026.
Abizer Gaslightwala, Director, President and CEO of Akari Therapeutics, will provide a corporate overview during the presentation. He will highlight the company’s next-generation antibody drug conjugate platform and proprietary PH1 spliceosome-modulating payload.
Gaslightwala will discuss Akari’s lead program, AKTX-101, a Trop2-targeting ADC designed to deliver PH1 directly to tumors with limited off-target effects. He will also provide updates on ongoing IND-enabling activities, targeting a first-in-human trial in late 2026 or early 2027.
An update on AKTX-102, an additional ADC program focused on GI and lung cancers, will also be provided.
The presentation is scheduled for Tuesday, February 10, 2026, at 1:00 PM EST. Registration details are available via the provided link.
Webull Financial, a leading online brokerage platform, empowers self-directed investors with tools and technology. It offers low-cost trading, charting tools, and real-time market data.
Akari Therapeutics is focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. The company’s ADC discovery platform enables the generation of ADC candidates, optimized for application to any antigen target of interest.
Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and uses a proprietary linker to deliver the PH1 payload directly into the tumor with minimal off-target effects. The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing within cancer cells.
Preclinical animal models have demonstrated that this splicing modulation induces cancer cell death while activating the innate and adaptive immune system. AKTX-101 has also shown significant activity and prolonged survival in preclinical studies, relative to ADCs with traditional payloads.
AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload is active against cancer cells with oncogenic drivers such as KRAS, BRAF, ARV7, and FGFR3 fusions.
The company has initiated IND enabling studies for AKTX-101, targeting a First-In-Human trial by late 2026/early 2027, and is advancing AKTX-102, an ADC against a novel target relevant in GI and lung cancers.
Source: Akari Therapeutics
